Chemosensitivity test for carcinoma of digestive organs.
For the chemosensitivity for carcinoma of digestive organs, gastric, colorectal, and hepatic cancer tissues were examined using in vitro succinate dehydrogenase inhibition (SDI) test and in vivo subrenal capsule (SRC) assay. The chemosensitivity varied in the tissue. The origin of an organ tumor, histological differentiation, and difference of primary or metastatic lesions are critical for determining chemosensitivity. Biochemical analysis shows that antitumor drugs have an increased susceptibility in tissues with high activity of pyrimidine nucleotide synthesis.
Maehara
Y
Y
Department of Surgery II, Faculty of Medicine, Kyushu University, Fukoka, Japan.
Kohnoe
S
S
Sugimachi
K
K
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy; D015179:Colorectal Neoplasms / Q000188:drug therapy; D004067:Digestive System Neoplasms / Q000188:drug therapy*; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy; D013274:Stomach Neoplasms / Q000188:drug therapy; D013370:Subrenal Capsule Assay; D013385:Succinate Dehydrogenase / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D013385:Succinate Dehydrogenase